Tesamorelin
Research highlights
- ✓Half-size vial — less reconstituted peptide sitting in the fridge
- ✓May stimulate endogenous GH release via the GHRH receptor
- ✓Clinically studied for visceral adiposity reduction
- ✓Preserves pulsatile GH secretion pattern — more physiological than direct GH
Read Carl's plain-English guide: Tesamorelin on Peptide Carl ›
What is Tesamorelin?
Tesamorelin is a synthetic GHRH analogue that stimulates pituitary GH release. Uniquely, it has been studied in clinical settings for visceral-fat research in specific populations.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
Tesamorelin, explained
The short version: Tesamorelin is a lab-made copy of the full 44-amino-acid hormone that tells the pituitary to release growth hormone, with one small chemical tweak. It is one of the few compounds in this group that became a real medicine: the US FDA approved it as Egrifta in November 2010.
What it is
The hypothalamus makes growth hormone-releasing hormone (GHRH), a 44-amino-acid peptide that signals the pituitary to release growth hormone. Tesamorelin is that full natural sequence with a short fatty chain, a hexenoyl group, bolted onto the first amino acid. It is still short-lived: the FDA label lists an average half-life of 26 minutes in healthy volunteers and 38 minutes in people with HIV.
What the trials found
People on HIV treatment often build up deep belly fat around the organs, called visceral fat. Tesamorelin was tested against placebo in two phase 3 trials in exactly this group, and a pooled analysis of 806 patients appeared in the Journal of Clinical Endocrinology & Metabolism in 2010.
After 26 weeks, visceral fat measured by CT scan fell by about 15% relative to placebo, while the fat just under the skin hardly moved. Triglycerides dropped and IGF-1 rose. Patients who carried on for a further 26 weeks kept the reduction. On the back of this, the FDA approved it as Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Where the evidence stops
The label is blunt about the limits. Long-term heart benefit and safety were never studied, and it is not a weight-loss drug: the label calls its effect on body weight neutral. It also flags raised IGF-1, fluid retention and glucose intolerance, and rules it out in active cancer. Every one of those trial results comes from one group of people, using the licensed product. WADA lists tesamorelin as a prohibited substance at all times.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
A genuine approved medicine, but the solid data sits inside one narrow use: visceral fat in people with HIV.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Tesamorelin
No reviews from orders with Tesamorelin yet. Here is what recent customers said about ordering from us.
★★★★★
Communication with your team was quick and fast and the delivery was sooner than expected. Well done!
Sarel M. · 8 Oct 2026
★★★★★
The best service from start of order to delivery, and definitely the products are the best of the best! Im hooked!
Shannon O. · 8 Oct 2026
★★★★★
Youre the best Thankyou!!
Rosemary V. · 8 Oct 2026
★ 4.8 across all 21 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
